What HotSpot Therapeutics does

HotSpot Therapeutics is a privately held, Boston-based clinical-stage biotechnology company founded in 2016 by Jonathan Montagu (CEO) and Geraldine Harriman (CSO), both former Nimbus Therapeutics executives. The company is developing a pipeline of allosteric small molecule therapies for autoimmune disease and oncology, anchored by its proprietary Smart Allostery™ drug discovery platform. Smart Allostery integrates structure-function analysis, pharmacology, tailored chemistry, and AI capabilities to systematically identify and drug natural hotspots — regulatory pockets on proteins that conventional active-site chemistry cannot reach — with the stated ambition of addressing roughly 85% of human proteins considered undruggable by traditional approaches. The technology stack comprises three components: SpotFinder™ (an AI engine that has identified ~1,500 proteins containing natural hotspots), SpotCapture (a suite of biochemical and in silico assays for confirming hotspot druggability), and SpotBinder (a custom ~800-million molecule library tailored to allosteric sites).

HotSpot's disclosed pipeline spans four programs. In inflammation, HST-2011 is a first-in-class small-molecule IRF5 inhibitor advancing toward IND-enabling studies for systemic lupus erythematosus, Sjögren's disease, rheumatoid arthritis, systemic sclerosis, and myositis. In oncology, HST-1011 is an oral CBL-B inhibitor currently in Phase 1 clinical trials for solid tumors with reported dose-dependent pharmacokinetics and target engagement; the CBM signalosome program targets KRAS G12X-driven colorectal, pancreatic, and lung cancers on the basis of synthetic-lethal biology; and an undisclosed immunology target extends the platform's footprint. The company has selectively partnered for oncology and intends to focus internal resources on immunology.

HotSpot operates a pre-commercial R&D business model: it has no marketed products, does not disclose revenue, and is funded almost entirely by equity capital — approximately $190 million raised through a 2017 Series A ($45M, Atlas Venture/Sofinnova), 2020 Series B (~$65M), and November 2021 Series C ($100M, led by Pivotal bioVenture Partners). The revenue pathway is forward-looking and contingent on (a) potential partnership or out-licensing transactions for selected assets, (b) future drug commercialization if assets are taken to market independently, and (c) the residual long-term value of the platform's pipeline optionality. Customer-facing activity today centers on scientific engagement (presentations at EULAR, ESMO, ASH, AACR, SITC, FOCIS) aimed at attracting pharma partners and supporting future financing.

Name

HotSpot Therapeutics

Legal name

HotSpot Therapeutics, Inc.

Website

https://hotspotthera.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

HotSpot Therapeutics is a Boston-based, clinical-stage biotechnology company developing allosteric small molecule therapies for autoimmune disease and oncology, using its AI-integrated Smart Allostery™ platform to drug natural hotspots on previously undruggable proteins.

Ownership category

akta.pro rank

Product category

Allosteric Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Allosteric drug discovery
• Small molecule therapeutics
• Autoimmune disease therapies
• Oncology drug discovery
• AI protein targeting

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Potential Commercialization: As a pre-commercial biotechnology company, HotSpot Therapeutics is developing a pipeline of allosteric small molecule therapeutic candidates across autoimmune diseases and oncology. The company is advancing programs through clinical development stages, with HST-1011 (CBL-B inhibitor) in Phase 1 clinical trials for solid tumors, and multiple programs in earlier stages including IRF5 inhibitors for autoimmune diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

HotSpot Therapeutics operates a proprietary AI-powered drug discovery platform called Smart Allostery™ that systematically identifies and targets natural hotspots (regulatory allosteric pockets) on proteins to develop small molecule therapeutics. The company applies this platform to build a clinical pipeline of allosteric inhibitors, including an IRF5 inhibitor (HST-2011) for autoimmune diseases and a CBL-B inhibitor (HST-1011, currently in Phase 1) and CBM signalosome inhibitors for solid tumors.

Product overview

HotSpot Therapeutics is pioneering a new class of allosteric medicines for the treatment of autoimmune diseases and cancer. The company's core offering is its proprietary Smart Allostery™ platform, which enables systematic identification and targeting of natural hotspots on proteins to discover differentiated allosteric small molecule inhibitors. The platform is applied across the company's therapeutic pipeline, which includes: the IRF5 inhibitor program (HST-2011) for multiple autoimmune diseases; the CBL-B inhibitor (HST-1011) for solid tumors currently in Phase 1; the CBM Signalosome program targeting KRAS G12X solid tumors; and an undisclosed immunology program. This is a unified platform-plus-pipeline approach where the Smart Allostery™ technology powers discovery across all therapeutic candidates.

Differentiator

Problem solved

Functional benefit

Products and services

• Smart Allostery™ Platform

Quantifiable outcome

• Dose-dependent suppression of cytokine production in multiple human immune cell types
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Caris Life SciencescoreStrategic or Co-development PartnerProprietary collaboration leveraging Caris Life Sciences' data and analytics capabilities to examine the role of the CBM complex in real-world patient data. This partnership enabled generation of novel data demonstrating the synthetic lethal relationship between KRAS G12X and the CBM signalosome.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Morphic Holding: Morphic is a clinical-stage biotech developing oral integrin allosteric inhibitors, sharing HotSpot's allosteric-modulator drug discovery approach. Both companies target previously undruggable biology through engineered small molecules that bind non-active-site pockets, making Morphic the closest direct comparator.
• Black Diamond Therapeutics: Black Diamond discovers allosteric inhibitors of oncogenic mutations, sharing HotSpot's platform thesis that allosteric sites unlock previously undruggable cancer targets. Both are clinical-stage companies applying computational/structural biology to allosteric oncology targets.
• Schrödinger, Inc. Schrödinger is a leader in computational/AI-driven drug discovery, applying physics-based modeling and machine learning to accelerate small molecule design. While broader in scope, it shares HotSpot's AI/ML-enabled drug discovery approach and serves as a benchmark for platform-led biotech valuations.
• Relay Therapeutics: Relay uses motion-based computational approaches to drug targets and has a clinical-stage precision oncology pipeline, including KRAS programs. Its platform thesis and oncology focus overlap with HotSpot's CBM signalosome and CBL-B programs.
• Revolution Medicines: Revolution Medicines is a leading KRAS-focused oncology company with clinical-stage assets targeting KRAS G12X variants. HotSpot's CBM signalosome program addresses the same KRAS-driven colorectal, pancreatic, and lung cancer indications, making Revolution a relevant competitive benchmark.
• Erasca: Erasca develops precision oncology drugs targeting the RAS/MAPK pathway, overlapping with HotSpot's oncology programs in KRAS-driven tumors. Both companies compete in the same indication space and have pursued substantial venture capital to fund clinical development.
• Recursion Pharmaceuticals: Recursion is an AI/ML-driven drug discovery company using high-throughput biology and machine learning to discover therapeutics, sharing HotSpot's AI-enabled discovery platform thesis. Both have raised substantial private capital to scale their respective platform-plus-pipeline models.

Broad incumbents

• Nimbus Therapeutics: Nimbus is a computational drug discovery company from which HotSpot's founders (Montagu and Harriman) previously spun out, and it remains a strategic reference point. Nimbus has executed large partnership deals (e.g., Gilead) validating the computational discovery business model that HotSpot's Smart Allostery platform extends into allosteric space.

Emerging players

• Generate Biomedicines: Generate applies generative AI to design novel proteins and biologics, sharing HotSpot's AI/ML-discovery platform DNA. While focused on biologics rather than small molecules, both companies represent the emerging class of generative/AI-native drug discovery platforms.
• Insitro: Insitro combines machine learning with high-throughput biology to discover therapeutics, sharing HotSpot's AI-driven discovery philosophy. It represents a parallel example of a venture-backed, platform-led biotech that is selectively bringing programs into internal development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/hotspotthera
• LinkedInlinkedin.com/company/hotspot-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HotSpot Therapeutics